hemCheck Sweden AB (publ.) is developing and commercializing a novel product concept (HELGE™) that detects hemolysis in blood samples at the point of care.
Hemolysis, or the rupturing of red blood cells, is the most common reason for blood samples to be deemed unfit for laboratory analysis. When a blood sample cannot be analyzed, it results in delayed treatment entailing increased risks for patients and higher costs for clinics. hemCheck offers a solution to this global problem by providing a fast and reliable test that makes every sample count. hemCheck Sweden AB (publ.) is a privately held medical technology company based in Karlstad, Sweden. hemCheck was founded in 2010 based on an invention by Dr. Mathias Karlsson.